Study: NCT04308135

Intervention type: DIAGNOSTIC_TEST
Intervention: non-motor symptoms scales (NMSS).
Description: Clinical Tool for assessment of non-motor symptoms of PD

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
Description: Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
Description: Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS

Intervention type: DIAGNOSTIC_TEST
Intervention: Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):
Description: Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS

Intervention type: DIAGNOSTIC_TEST
Intervention: ELIZA for alpha-synuclein
Description: measuring serum of alpha-synuclein, tau and their autoantibodoies

Intervention type: DIAGNOSTIC_TEST
Intervention: ELIZA for alpha-synuclein
Description: measuring serum of alpha-synuclein, tau and their autoantibodoies

Intervention type: OTHER
Intervention: transcranial color-coded duplex(TCCD)
Description: TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.

Intervention type: OTHER
Intervention: transcranial color-coded duplex(TCCD)
Description: TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.

Intervention type: OTHER
Intervention: transcranial color-coded duplex(TCCD)
Description: TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.

Intervention type: OTHER
Intervention: extracranial carotid duplex
Description: to assess atherosclerosis, stenosis of carotids

Intervention type: OTHER
Intervention: extracranial carotid duplex
Description: to assess atherosclerosis, stenosis of carotids

Intervention type: OTHER
Intervention: extracranial carotid duplex
Description: to assess atherosclerosis, stenosis of carotids

Intervention type: OTHER
Intervention: The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)
Description: Clinical tool for quality of life of PD patients

Intervention type: OTHER
Intervention: The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)
Description: Clinical tool for quality of life of PD patients

Intervention type: OTHER
Intervention: The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)
Description: Clinical tool for quality of life of PD patients